Akero Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Akero Therapeutics, Inc. - overview
Established
2017
Location
South San Francisco, CA-California, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in California, US, Akero Therapeutics, Inc. operates as a biotechnology that develops treatment of non-alcoholic steatohepatitis and other metabolic disorders that target the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis. In March 2024, Akero Therapeutics Inc. raised USD 319 million in a private placement, selling 11 million shares at USD 29 per share on the Nasdaq Global Select Market under the ticker symbol "AKRO".
Akero Therapeutics Inc. has granted the underwriters a 30-day option to purchase up to an additional 1. 65 million shares of common stock as part of the listing. Akero Therapeutics developes therapies for serious metabolic diseases, to improve patients' lives.
The company with its lead program, Efruxifermin (EFX), focuses on addressing metabolic dysfunction-associated steatohepatitis (MASH).
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.akerotx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.